- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04590885
Coping Together: Couple-based Interventions for Cancer (CCST2)
Couple Communication Skills Training for Advanced Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For patients and their intimate partners, advanced cancer poses significant challenges that can negatively impact both individuals and the couple's collective well-being. Couples' ability to communicate openly and effectively with each other about cancer-related concerns can improve their psychological adjustment and quality of their relationship. Open and effective communication may also lead to better symptom management and goal-concordant care. However, many couples report difficulties communicating about cancer, even in the context of overall satisfying relationships. This can have a number of deleterious consequences, including deficits in emotional support, decreases in intimacy and relationship quality, and increased psychological distress. Thus, interventions designed to facilitate effective communication between cancer patients and their partners are likely to have beneficial effects on both individual and relationship functioning.
Prior research, including studies conducted by our team, has found that couple-based interventions that target communication lead to positive outcomes for cancer patients and their partners. However, most prior studies have been limited by reliance on an in-person treatment delivery format which keeps many couples from participating. In addition, prior studies have not targeted interventions to couples who are most likely to benefit. There is increasing evidence that psychosocial interventions for cancer, including couple-based interventions, should be targeted to those at risk of poor outcomes. Our prior research indicates that couples who report communication difficulties (e.g., high levels of holding back from discussing cancer-related concerns) have increased psychological distress and poorer relationship functioning and are most likely to benefit from a couple communication intervention specifically designed to addressed their communication problems.
The specific aims of this study are (1)To determine whether CCST significantly improves patients' and partners' individual psychological adjustment (i.e., psychological distress, life completion) and patient health and health care outcomes (physical well-being, symptom distress, advance care planning discussions and completion of advance directives, hospitalizations, and emergency department visits) compared to an education condition. (2) To determine whether, for couples receiving the CCST intervention, improvements in psychological adjustment, relationship functioning, and patient health are mediated by improvements in their communication, including objective measures of communication quality and communal coping (e.g., "we-talk") derived from couple conversations and self-reported protective buffering. (3) To examine differences in response to the CCST intervention for patients versus partners, for male versus female participants, and for patients with different cancer diagnoses (breast, lung, GI, GU). (4) To conduct an implementation-related process evaluation of the intervention.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laura Porter, PhD
- Phone Number: 919-416-3436
- Email: Laura.Porter@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University Medical Center
-
Contact:
- Laura Porter, Ph.D
- Phone Number: 919-416-3436
- Email: porte008@mc.duke.edu
-
Principal Investigator:
- Laura Porter, Ph.D
-
Principal Investigator:
- Francis Keefe, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Married or in a committed intimate relationship
- Diagnosis of one the following advanced cancers: Stage IIIB or IV non-small cell lung cancer or extensive stage small cell lung cancer, Stage III pancreatic cancer or Stage IV GI cancer, Stage IV GU cancer, Stage IV breast cancer and GYN cancer Stage III-IV ovarian, IV uterine, IV cervical.
- Both members of the couple must speak and read English.
- Patient and/or partner scores >=1.0 on the Holding Back screen.
Exclusion Criteria:
- Patient lacks capacity for interview (documented diagnosis of active psychosis or dementia) or is unable to provide informed consent as assessed by research staff.
- Patient has a life expectancy < 6 months as estimated by his/her treating oncologist.
- Patient or partner is physically impaired in such a way that precludes the use of a computer or videoconferencing.
- Patient or partner is too sick to participate, as judged by the oncologist or research staff.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Couple Communication and Support
CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support.
It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving.
Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
|
Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
Other Names:
|
Other: Healthy Lifestyle Informaion
Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment.
Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care.
Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
|
Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in patient relationship functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in partner relationship functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in partner relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient relationship functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in partner relationship functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in partner intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in partner psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in partner psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in partner psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in partner mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient life completion measured by the Life Completion scale of the QUAL-E (higher scores indicate higher completion)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in partner psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in partner life completion measured by the Life Completion scale of the QUAL-E Family (higher scores indicate higher completion)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient physical well being as measured by the Physical Well Being subscale of the Functional Assessment of Cancer Therapy scale (higher scores indicate higher physical well being)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient and partner psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in symptom distress as measured by the Condensed Memorial Symptom Assessment Scale (higher scores indicate higher symptom distress)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient advance care planning discussions (presence or absence, via patient self-report)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient completion of advanced directives (presence or absence, via patient self-report)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient hospitalizations (number of hospitalizations per patient self-report, validated by medical record review)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Changes in patient psychological functioning
Time Frame: Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Change in patient emergency department visits (number of emergency department visits per patient self-report, validated by medical record review)
|
Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Porter, PhD, Duke
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00103232
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
-
Bristol-Myers SquibbActive, not recruitingAdvanced CancerFrance, United States, Spain, Canada, Argentina, Chile, Italy
Clinical Trials on Couple Communication Skills Training
-
University Hospital, Basel, SwitzerlandUniversity of Basel; Max Planck Institute for Human DevelopmentCompletedInformation Structuring Skills | Empathy SkillsSwitzerland
-
Jules Bordet InstituteUniversité Catholique de Louvain; Université Libre de Bruxelles; Université de... and other collaboratorsUnknownPhysician Patient RelationshipBelgium
-
Montefiore Medical CenterRecruitingCritical Illness | Terminal IllnessUnited States
-
US Department of Veterans AffairsCompleted
-
University of St AndrewsNHS Lothian; Breast Cancer NowUnknownBreast CancerUnited Kingdom
-
Tulane University School of MedicineRobert Wood Johnson FoundationCompletedCervical Cancer | Breast Cancer | Colorectal CancerUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Mental Health (NIMH)CompletedMental Disorders Diagnosed in ChildhoodUnited States
-
Universitätsklinikum Hamburg-EppendorfRecruiting
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Mental Health (NIMH)Completed